BR9804504A - Isoquinolina-3-carboxamidas substituìdas, sua preparação e seu uso como substâncias farmacêuticas - Google Patents

Isoquinolina-3-carboxamidas substituìdas, sua preparação e seu uso como substâncias farmacêuticas

Info

Publication number
BR9804504A
BR9804504A BR9804504-0A BR9804504A BR9804504A BR 9804504 A BR9804504 A BR 9804504A BR 9804504 A BR9804504 A BR 9804504A BR 9804504 A BR9804504 A BR 9804504A
Authority
BR
Brazil
Prior art keywords
isoquinoline
chlorine
hydrogen
preparation
pharmaceutical substances
Prior art date
Application number
BR9804504-0A
Other languages
English (en)
Other versions
BR9804504B1 (pt
Inventor
Klaus Dr Weidmann
Karl Heinz Dr Baringhaus
Georg Dr Tschank
Ulrich Dr Werner
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of BR9804504A publication Critical patent/BR9804504A/pt
Publication of BR9804504B1 publication Critical patent/BR9804504B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Patente de Invenção: <B>"ISOQUINOLINA-3-CARBOXAMIDAS SUBSTITUìDAS, SUA PREPARAçãO E SEU USO COMO SUBSTâNCIAS FARMACêUTICAS"<D>. As isoquinolina-3-carboxamidas da fórmula I em que R~ 1~ é hidrogênio ou cloro, R² é hidrogênio, alquila, alcóxi, cloro, trifluormetila, hidroxila, ou benzilóxi, o qual é opcionalmente substituído, ou fluoralcóxicóxi da fórmula O-[CH~ 2~]~ x~-C~ f~H~ (2f+1-g)~F~ g~, onde x = 0 ou 1, f = 1 - 5 e g = 1 a (2f+1), R³ é hidrogênio, alquila, alcóxi, flúor, cloro, ciano, trifluormetila, hidroxila, ou benzilóxi, o qual é opcionalmente substituído, ou fluoralcóxicóxi da fórmula acima descrita, R^ 4^ e R^ 5^ são hidrogênio, alquila, flúor, cloro, bromo, trifluormetila, ciano, alcóxi, ou fluoralcóxicóxi da fórmula acima descrita, incluindo os sais fisiologicamente ativos, são inibidoras fortes de prolil-4-hidroxilase, os quais não causam a esteatose.
BRPI9804504-0A 1997-10-20 1998-10-19 isoquinolina-3-carboxamidas substituÍdas, processo para a preparaÇço das mesmas e medicamento. BR9804504B1 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19746287A DE19746287A1 (de) 1997-10-20 1997-10-20 Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel

Publications (2)

Publication Number Publication Date
BR9804504A true BR9804504A (pt) 2001-05-22
BR9804504B1 BR9804504B1 (pt) 2009-01-13

Family

ID=7846053

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9804504-0A BR9804504B1 (pt) 1997-10-20 1998-10-19 isoquinolina-3-carboxamidas substituÍdas, processo para a preparaÇço das mesmas e medicamento.

Country Status (25)

Country Link
US (1) US6093730A (pt)
EP (2) EP1538160B1 (pt)
JP (2) JP3782591B2 (pt)
KR (1) KR100618922B1 (pt)
CN (1) CN1117079C (pt)
AR (1) AR013696A1 (pt)
AT (2) ATE299148T1 (pt)
AU (1) AU755714B2 (pt)
BR (1) BR9804504B1 (pt)
CA (2) CA2250664A1 (pt)
CZ (1) CZ337298A3 (pt)
DE (3) DE19746287A1 (pt)
DK (2) DK1538160T3 (pt)
ES (2) ES2328156T3 (pt)
HK (1) HK1019605A1 (pt)
HU (1) HUP9802422A3 (pt)
ID (1) ID21115A (pt)
IL (1) IL126638A0 (pt)
NO (1) NO312365B1 (pt)
NZ (1) NZ332363A (pt)
PL (1) PL192354B1 (pt)
PT (1) PT911340E (pt)
SG (1) SG87776A1 (pt)
TR (1) TR199802106A2 (pt)
ZA (1) ZA989505B (pt)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001275014A1 (en) * 2000-05-30 2001-12-11 Neurogen Corporation Imidazoloisoquinolines
US6762318B2 (en) * 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
AU2002362065B2 (en) * 2001-12-06 2007-12-06 Fibrogen, Inc. Stabilization of hypoxia inducible factor (HIF) alpha
EP2295060B1 (en) 2001-12-06 2018-10-31 Fibrogen, Inc. Treatment or prevention of ischemic or hypoxic conditions
US8318703B2 (en) 2001-12-06 2012-11-27 Fibrogen, Inc. Methods for improving kidney function
US7618940B2 (en) * 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8124582B2 (en) * 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
WO2005007192A2 (en) * 2003-06-06 2005-01-27 Fibrogen, Inc. Cytoprotection through the use of hif hydroxylase inhibitors
EP2357175A1 (en) * 2003-06-06 2011-08-17 Fibrogen, Inc. isoquinoline derivatives AND THEIR USE IN INCREASING ENDOGENEOUS ERYTHROPOIETIN
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
CA2610956A1 (en) * 2005-06-06 2006-12-14 Fibrogen, Inc. Improved treatment for anemia using a hif-alpha stabilising agent
ATE470439T1 (de) 2005-06-15 2010-06-15 Fibrogen Inc Verwendung von hif 1alfa modulatoren zur behandlung von krebs
CA2634168C (en) 2005-12-09 2013-04-23 Amgen Inc. Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof
US7928120B2 (en) * 2006-01-27 2011-04-19 Fibrogen, Inc. Cyanoisoquinoline compounds and methods of use thereof
US7625927B2 (en) 2006-02-27 2009-12-01 Alcon Research, Ltd. Method of treating glaucoma
US7745461B1 (en) 2006-02-27 2010-06-29 Alcon Research, Ltd. Method of treating dry eye disorders
EP2025170B1 (en) * 2006-03-30 2015-01-07 LG Electronics Inc. A method and apparatus for decoding/encoding a video signal
CN101460497A (zh) 2006-04-04 2009-06-17 菲布罗根有限公司 作为hif调节剂的吡咯并吡啶和噻唑并吡啶化合物
EP3026044B8 (en) 2006-06-26 2018-12-19 Akebia Therapeutics, Inc. Prolyl hydroxylase inhibitors and methods of use
EP2111399A2 (en) 2006-12-18 2009-10-28 Amgen Inc. Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
ES2393326T3 (es) 2006-12-18 2012-12-20 Amgen, Inc Compuestos basados en azaquinolona que presentan actividad inhibidora de prolil hidroxilasas, composiciones y usos de los mismos
EP2155680B1 (en) 2007-04-18 2013-12-04 Amgen, Inc Indanone derivatives that inhibit prolyl hydroxylase
US8048894B2 (en) 2007-04-18 2011-11-01 Amgen Inc. Quinolones and azaquinolones that inhibit prolyl hydroxylase
US8030346B2 (en) 2007-05-04 2011-10-04 Amgen Inc. Heterocyclic quinolone derivatives that inhibit prolyl hydroxylase activity
EP2155746A2 (en) 2007-05-04 2010-02-24 Amgen, Inc Diazaquinolones that inhibit prolyl hydroxylase activity
WO2009002533A1 (en) * 2007-06-27 2008-12-31 The Brigham And Women's Hospital, Inc. Inflammatory bowel disease therapies
CN101497584B (zh) * 2008-01-29 2010-12-22 首都医科大学 异喹啉-3-甲酰氨基酸苄酯及其制备和应用
CN102076680B (zh) 2008-04-28 2016-03-02 詹森药业有限公司 作为脯氨酰羟化酶抑制剂的苯并咪唑
WO2010056767A1 (en) 2008-11-14 2010-05-20 Fibrogen, Inc. Thiochromene derivatives as hip hydroxylase inhibitors
US8283465B2 (en) * 2009-07-17 2012-10-09 Japan Tobacco Inc. Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor or erythropoietin production-inducing agent
NO2686520T3 (pt) 2011-06-06 2018-03-17
AU2012289429B2 (en) * 2011-07-22 2016-07-28 Beijing Betta Pharmaceuticals Co., Ltd Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof
ES2689481T3 (es) 2011-10-25 2018-11-14 Janssen Pharmaceutica Nv Formulaciones de sal de meglumina de ácido 1-(5,6-dicloro-1h-benzo[d]imidazol-2-il)-1h-pirazol-4-carboxílico
SG11201405574UA (en) 2012-03-09 2014-10-30 Fibrogen Inc 4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors
CN115093370A (zh) 2012-07-16 2022-09-23 菲布罗根有限公司 脯氨酰羟化酶抑制剂的晶体形态
ES2631655T3 (es) 2012-07-16 2017-09-01 Fibrogen, Inc. Procedimiento para fabricar compuestos de isoquinolina
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
US9822135B2 (en) 2012-10-30 2017-11-21 H. Lee Moffitt Cancer Center And Research Institute, Inc. STAT3 dimerization inhibitors
CN105452227B (zh) 2013-01-24 2018-05-29 菲布罗根有限公司 {[1-氰基-5-(4-氯苯氧基)-4-羟基-异喹啉-3-羰基]-氨基}-乙酸的晶形
MX2015016536A (es) 2013-06-06 2016-08-11 Fibrogen Inc Formulaciones farmacéuticas de un inhibidor de hidroxilasa de hif.
PE20201496A1 (es) 2013-06-13 2020-12-29 Akebia Therapeutics Inc Composiciones y metodos para tratar anemia
MX2021001169A (es) 2013-11-15 2023-02-10 Akebia Therapeutics Inc Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acético, composiciones, y usos de las mismas.
ES2820226T3 (es) 2014-05-15 2021-04-20 Insmed Inc Métodos para tratar infecciones pulmonares micobacterianas no tuberculosas
CN107427503A (zh) 2015-01-23 2017-12-01 阿克比治疗有限公司 2‑(5‑(3‑氟苯基)‑3‑羟基吡啶甲酰胺)乙酸的固体形式、其组合物及用途
KR20240038132A (ko) 2015-04-01 2024-03-22 아케비아 테라퓨틱스 인코포레이티드 빈혈 치료용 조성물 및 방법
US20180243271A1 (en) * 2015-05-28 2018-08-30 Japan Tobacco Inc. Method for Treating or Preventing Diabetic Nephropathy
AU2016291228B2 (en) * 2015-07-09 2020-04-09 Insmed Incorporated Compositions and methods for treating lung diseases and lung injury
AR108325A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
AR108326A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
CN111819190A (zh) * 2018-01-09 2020-10-23 康奈尔大学 器官纤维化的预防和治疗
EP3773505A4 (en) 2018-03-30 2021-12-22 Insmed Incorporated PROCESS FOR THE CONTINUOUS MANUFACTURING OF LIPOSOMAL MEDICINAL PRODUCTS
AR114886A1 (es) 2018-05-09 2020-10-28 Akebia Therapeutics Inc Proceso para preparar ácido 2-[[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino]acético
US20210299116A1 (en) * 2018-08-03 2021-09-30 Cornell University Methods for reducing abnormal scar formation
TW202120490A (zh) 2019-07-30 2021-06-01 德商拜耳動物保健有限公司 新穎異喹啉衍生物
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
CN112979541B (zh) * 2019-12-17 2022-11-11 浙江大学 一种基于n-(3-羟基吡啶-2-羰基)甘氨酸的抗肿瘤药物增敏剂及其应用
CN116120340B (zh) * 2021-11-15 2023-10-31 艾立康药业股份有限公司 一种吡啶并噁嗪类化合物及其制备方法、组合物和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4015255A1 (de) * 1990-05-12 1991-11-14 Hoechst Ag Oxalyl-aminosaeurederivate, verfahren zu ihrer herstellung und ihrer verwendung als arzneimittel zur inhibierung der prolyl-hydroxylase
CA2085954A1 (en) * 1991-12-24 1993-06-25 Klaus Weidmann Substituted pyridine n-oxides, processes for their preparation, and their use
TW352384B (en) * 1992-03-24 1999-02-11 Hoechst Ag Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
DE4233124A1 (de) * 1992-10-02 1994-04-07 Hoechst Ag Acylsulfonamido- und Sulfonamidopyridin-2-carbonsäureester sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DK0650960T3 (da) * 1993-11-02 1997-09-01 Hoechst Ag Substituerede heterocykliske carboxylsyreamid-estere, deres fremstilling og deres anvendelse som lægemidler.
ES2101421T3 (es) * 1993-11-02 1997-07-01 Hoechst Ag Amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos.
TW406076B (en) * 1993-12-30 2000-09-21 Hoechst Ag Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
SE9400810D0 (sv) * 1994-03-10 1994-03-10 Pharmacia Ab New use of Quinoline-3-carboxamide compounds
IL135495A (en) * 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid

Also Published As

Publication number Publication date
CZ337298A3 (cs) 1999-05-12
PL192354B1 (pl) 2006-10-31
KR19990037182A (ko) 1999-05-25
TR199802106A3 (tr) 1999-05-21
EP0911340A2 (de) 1999-04-28
CA2251647A1 (en) 1999-04-20
JP2006056894A (ja) 2006-03-02
NO984877L (no) 1999-04-21
HU9802422D0 (en) 1998-12-28
ES2245471T3 (es) 2006-01-01
PL329274A1 (en) 1999-04-26
EP0911340B1 (de) 2005-07-06
KR100618922B1 (ko) 2007-04-25
JP4691419B2 (ja) 2011-06-01
DE59814365D1 (de) 2009-07-16
EP0911340A3 (de) 1999-07-07
IL126638A0 (en) 1999-08-17
NO312365B1 (no) 2002-04-29
EP1538160B1 (de) 2009-06-03
ATE432940T1 (de) 2009-06-15
EP1538160A1 (de) 2005-06-08
DE59812907D1 (de) 2005-08-11
US6093730A (en) 2000-07-25
HUP9802422A2 (hu) 1999-08-30
AU8941398A (en) 1999-05-06
CA2250664A1 (en) 1999-04-20
ATE299148T1 (de) 2005-07-15
CN1117079C (zh) 2003-08-06
ID21115A (id) 1999-04-22
PT911340E (pt) 2005-09-30
AU755714B2 (en) 2002-12-19
DK1538160T3 (da) 2009-10-05
DK0911340T3 (da) 2005-11-07
HK1019605A1 (en) 2000-02-18
CN1218802A (zh) 1999-06-09
CA2251647C (en) 2011-08-30
HUP9802422A3 (en) 2002-02-28
DE19746287A1 (de) 1999-04-22
TR199802106A2 (xx) 1999-05-21
NZ332363A (en) 2000-04-28
AR013696A1 (es) 2001-01-10
NO984877D0 (no) 1998-10-19
JPH11302257A (ja) 1999-11-02
ZA989505B (en) 1999-04-20
ES2328156T3 (es) 2009-11-10
SG87776A1 (en) 2002-04-16
JP3782591B2 (ja) 2006-06-07
BR9804504B1 (pt) 2009-01-13

Similar Documents

Publication Publication Date Title
BR9804504A (pt) Isoquinolina-3-carboxamidas substituìdas, sua preparação e seu uso como substâncias farmacêuticas
BR9812010A (pt) Determinados ácidos 5-alquil-2-arilaminofenilacéticos e derivados
EA200300873A1 (ru) Новая соль сукцинат o-десметилвенлафаксина
EA199800579A1 (ru) Новые производные 5-амино-3-циано-4-этилсульфинил-1-фенилпиразола и их применение в качестве пестицидов
DK1077928T3 (da) Nye substituerede cykliske forbindelser, fremgangsmåder til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse
BR9915735A (pt) Antagonistas receptores de ccr-3 de piperidina
LV12639B (lv) Bifenilsulfonamidi ka duali angiotenzina un endotelina receptoru antagonisti
EA200000759A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
BR9803179A (pt) Antagonistas receptores de ccr-3.
EA200201179A1 (ru) Производные 2-аминокарбонил-9h-пурина
NO20026094L (no) Kondenserte azepinderivater og deres anvendelse som antidiuretiske midler
IS6257A (is) Frumuviðloðunartálmar
DK188288D0 (da) 1-phenyl-3-naphthalenyloxypropanaminer, fremgangsmaade til fremstilling af saadanne forbindelser og farmaceutiske midler indeholdende disse
BR9814832A (pt) Composto, e, herbicida
ES2150544T3 (es) Dihidropiridinas de accion breve.
DE60101372D1 (de) Pyrimidinverbindungen und ihre verwendung als modulatoren der chemokin-rezeptor-aktivität
FI925848A0 (fi) Tizolidinfoereningar, som innehaoller en kinogrupp, deras framstaellning och terapeutiska anvaendningar
FI844333A0 (fi) 11-substituerade 5h,11h-pyrrolo/2,1-c/ /1,4/benzoxazepiner, foerfarande foer deras framstaellning och deras anvaendning som laekemedel.
EA200400806A1 (ru) Способ получения эхинокандиновых соединений
SE8500107D0 (sv) Neue 8alfa-acylaminoergoline
EA200100618A1 (ru) Антагонист витронектинового рецептора
BR9907497A (pt) Compostos de imidazolina, um processo para seu preparo e compostos farmacêuticos contendo os mesmos
FI945582A0 (fi) Substituoidut (aryylialkyyliaminobentsyyli) aminopropioniamidijohdannaiset, niiden valmistus ja käyttö anti-epileptisinä, neuroprotektiivisina ja antidepressiivisina aineina
DK1086071T3 (da) Hyperforinforbindelser, anvendelse heraf og formuleringer indeholdende disse
FI973111A (fi) Substituoidut fenyyliyhdisteet endoteliiniantagonisteina

Legal Events

Date Code Title Description
TC Change of name
B25A Requested transfer of rights approved

Free format text: AWEGA PATENTMANAGEMENT GMBH (DE)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B25A Requested transfer of rights approved

Owner name: FIBROGEN, INC. (US)

Free format text: TRANSFERIDO DE: AWEGA PATENTMANAGEMENT GMBH

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 13/01/2009, OBSERVADAS AS CONDICOES LEGAIS.

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 13.01.2019